See more : World Quantum Growth Acquisition Corp. (WQGA-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Ocugen, Inc. (OCGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocugen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- AAA Technologies Limited (AAATECH.BO) Income Statement Analysis – Financial Results
- Triton International Limited (TRTN-PD) Income Statement Analysis – Financial Results
- Telefónica Deutschland Holding AG (0QAL.IL) Income Statement Analysis – Financial Results
- Net One Systems Co., Ltd. (NONEY) Income Statement Analysis – Financial Results
- W.I.S.E. – SSE 50 China Tracker (3024.HK) Income Statement Analysis – Financial Results
Ocugen, Inc. (OCGN)
About Ocugen, Inc.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.04M | 2.49M | 0.00 | 42.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 26.00K |
| Cost of Revenue | 704.00K | 1.07M | 589.00K | 6.35K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.33M | 1.42M | -589.00K | 36.27K | -60.61K | -49.62K | -1.53M | -1.67M | -1.61M | 0.00 | 8.00K | 26.00K |
| Gross Profit Ratio | 88.34% | 56.87% | 0.00% | 85.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 39.57M | 49.76M | 35.11M | 6.35M | 8.09M | 15.63M | 15.57M | 21.58M | 23.24M | 25.86M | 11.95M | 11.94M |
| General & Administrative | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.99M | 35.11M | 22.92M | 7.97M | 6.08M | 10.20M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| Other Expenses | 0.00 | 3.52M | -310.00K | 182.66K | -784.87K | 1.43M | -116.00K | -248.00K | -72.00K | 13.00K | -52.00K | -30.00K |
| Operating Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Cost & Expenses | 71.57M | 84.87M | 58.03M | 14.33M | 14.16M | 25.84M | 24.95M | 30.11M | 31.51M | 32.60M | 16.79M | 14.99M |
| Interest Income | 0.00 | 1.40M | 0.00 | 1.07K | 1.21K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 79.00K | 720.96K | 1.77M | 163.00K | 134.00K | -60.00K | -133.00K | -151.00K | 0.00 | 798.00K |
| Depreciation & Amortization | 704.00K | 480.00K | 589.00K | 102.11K | 60.61K | 49.62K | 1.53M | 1.67M | 1.61M | 726.00K | 566.00K | 638.00K |
| EBITDA | -64.83M | -88.59M | -58.03M | -21.00M | -18.41M | -14.42M | -24.88M | -11.38M | -30.28M | -21.92M | -16.22M | -14.33M |
| EBITDA Ratio | -1,074.01% | -3,411.09% | 0.00% | -33,085.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -91,800.00% | -50,734.62% |
| Operating Income | -65.53M | -84.87M | -58.03M | -21.28M | -14.16M | -30.11M | -24.95M | -30.31M | -31.82M | -32.66M | -16.85M | -14.97M |
| Operating Income Ratio | -1,085.67% | -3,411.09% | 0.00% | -49,940.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -210,562.50% | -57,569.23% |
| Total Other Income/Expenses | 2.45M | 2.27M | -389.00K | -536.95K | -6.08M | 11.89M | -1.46M | 14.10M | -205.00K | 9.87M | -8.87M | -1.97M |
| Income Before Tax | -63.08M | -81.35M | -58.42M | -21.82M | -20.24M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Income Before Tax Ratio | -1,045.03% | -3,269.73% | 0.00% | -51,201.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| Income Tax Expense | 0.00 | -4.00M | -52.00K | 801.52K | 982.96K | -15.76M | -186.00K | -15.82M | -1.17M | -10.52M | 8.88M | 1.94M |
| Net Income | -63.08M | -77.83M | -58.37M | -22.62M | -21.23M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.94M |
| Net Income Ratio | -1,045.03% | -3,128.38% | 0.00% | -53,081.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -321,400.00% | -65,134.62% |
| EPS | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -68.21 | -145.22 | -891.47 | -120.93 | -79.65 |
| EPS Diluted | -0.26 | -0.36 | -0.30 | -0.20 | -1.53 | -13.98 | -69.91 | -67.58 | -145.22 | -891.47 | -120.93 | -79.65 |
| Weighted Avg Shares Out | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.83K | 237.62K | 220.52K | 25.57K | 212.62K | 212.62K |
| Weighted Avg Shares Out (Dil) | 244.33M | 214.60M | 195.01M | 112.24M | 13.89M | 618.18K | 377.84K | 239.82K | 220.52K | 25.57K | 212.62K | 212.62K |
OCGN DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN
NEW YORK , June 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class...
Holzer & Holzer, LLC Reminds Shareholders of June 10, 2024 Lead Plaintiff Deadline in Ocugen, Inc. (OCGN) Class Action – Investors With Losses In Excess of $50,000 Encouraged to Contact the Firm
ATLANTA, June 03, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material...
OCGN DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b)...
MMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and...
IMPORTANT DEADLINE UPDATE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b)...
MMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN). Such investors are advised to contact Danielle Peyton at [email protected] or...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(b)...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
NEW YORK , May 31, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and reminds investors of the June 10, 2024 deadline...
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
MALVERN, Pa., May 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced a positive outcome of the Data and...
Source: https://incomestatements.info
Category: Stock Reports